| BMRN |
BioMarin Pharmaceutical Inc. |
72%
|
ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale… |
| BMRN |
BioMarin Pharmaceutical Inc. |
72%
|
Reciprocal relationship from BMRN graph: Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respec… |
| MS-PE |
Morgan Stanley |
72%
|
Reciprocal relationship from MS-PE graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from MS-PE graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from MS-P… |
| MS-PK |
Morgan Stanley |
72%
|
written offering. The Offering closed on December 8, 2023, and the Company generated net proceeds of $ 282.0 million (€ 261.6 million), after deducting bank fees of $ 18.0 million (€ 16.7 million). T… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
Reciprocal relationship from MYGN graph: Reciprocal relationship from PHVS graph: Reciprocal relationship from MYGN graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our pro… |
| MYGN |
Myriad Genetics, Inc. |
72%
|
ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts … |
| RYTM |
Rhythm Pharmaceuticals, Inc. |
72%
|
Reciprocal relationship from RYTM graph: Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respec… |
| RYTM |
Rhythm Pharmaceuticals, Inc. |
72%
|
ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from PHVS graph: ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respe… |
| SNYNF |
Sanofi |
72%
|
ion), after deducting $0.3 million (€0.3 million), which was payable to Leerink Partners, LLC as commission in respect of such sales. The Company has not sold any securities under the April 2024 Sale… |
| ABBV |
AbbVie Inc. |
62%
|
Reciprocal relationship from ABBV graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to ge… |
| ABBVIE-DEUTSCHLAND-GMBH |
ABBVIE-DEUTSCHLAND-GMBH |
62%
|
ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts … |
| CO-LLC |
CO-LLC |
62%
|
written offering. The Offering closed on December 8, 2023, and the Company generated net proceeds of $ 282.0 million (€ 261.6 million), after deducting bank fees of $ 18.0 million (€ 16.7 million). T… |
| FMR-LLC |
FMR-LLC |
62%
|
and Inclusion Policy, the Company does report on its gender diversity targets. C. Board Pr actices Board Structure The Board is charged with the management of the Company, which includes setting the … |
| GAP-COINVESTMENTS-IV-LLC |
GAP-COINVESTMENTS-IV-LLC |
62%
|
and Inclusion Policy, the Company does report on its gender diversity targets. C. Board Pr actices Board Structure The Board is charged with the management of the Company, which includes setting the … |
| GAP-COINVESTMENTS-V-LLC |
GAP-COINVESTMENTS-V-LLC |
62%
|
and Inclusion Policy, the Company does report on its gender diversity targets. C. Board Pr actices Board Structure The Board is charged with the management of the Company, which includes setting the … |
| JANSSEN-BIOTECH-INC |
JANSSEN-BIOTECH-INC |
62%
|
ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts … |
| JNJ |
Johnson & Johnson |
62%
|
Reciprocal relationship from JNJ graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to gen… |
| LEERINK-PARTNERS-LLC |
LEERINK-PARTNERS-LLC |
62%
|
written offering. The Offering closed on December 8, 2023, and the Company generated net proceeds of $ 282.0 million (€ 261.6 million), after deducting bank fees of $ 18.0 million (€ 16.7 million). T… |
| LIFE-TECHNOLOGIES-CORP |
LIFE-TECHNOLOGIES-CORP |
62%
|
ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts … |
| LITB |
LightInTheBox Holding Co., Ltd. |
62%
|
Reciprocal relationship from LITB graph: Reciprocal relationship from PHVS graph: ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to ge… |
| PARTNERS-LLC |
PARTNERS-LLC |
62%
|
and Inclusion Policy, the Company does report on its gender diversity targets. C. Board Pr actices Board Structure The Board is charged with the management of the Company, which includes setting the … |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY |
PASSIVE-FOREIGN-INVESTMENT-COMPANY |
62%
|
nd €0.6 million, respectively. A new agreement was entered into with GrayMatters, effective December 1, 2023 to November 30, 2027. The agreement provides for daily fixed fees up to a maximum amount p… |
| PHARVARIS-HOLDINGS |
PHARVARIS-HOLDINGS |
62%
|
cted in the assumptions when they occur. Share-based payments The Group has adopted an equity-settled share-based compensation plan, pursuant to which certain participants are granted the right to ac… |
| PROMETHEUS-LABORATORIES-INC-PROMEGA-CORP |
PROMETHEUS-LABORATORIES-INC-PROMEGA-CORP |
62%
|
ates, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenues and profits. Moreover, increasing efforts … |
| QUESTCOR-PHARMACEUTICALS-INC |
QUESTCOR-PHARMACEUTICALS-INC |
62%
|
eveloped a broad human resources background, working in human resources leadership roles at European, international and global levels with companies such as Shire Pharmaceuticals (April 2018 - March … |
| SVB-SECURITIES-LLC |
SVB-SECURITIES-LLC |
62%
|
0 % 105 % 100 % 100 % 100 % Expected life (years) 5.5 6.1 6.1 6.1 5.5 6.1 6.1 6.1 Risk-free interest rate (%) 4.3 % 4.3 % 4.0 % 4.7 % 4.7 % 4.7 % 4.6 % 3.6 % Expected volatility in 2025, 2024 and 202… |
